Cytek Biosciences Q3 net loss widens to $6.1M

Cytek narrowed its full-year 2026 revenue outlook to $208 million to $211 million, assuming no change in current foreign currency exchange rates.

Available on EDGAR 11/04/2026 - 04:16 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Cytek Biosciences, Inc. reported third-quarter 2026 revenue of $53.2 million, up 2% year over year. GAAP gross profit was $31.2 million, up 13%; GAAP gross margin was 59%, versus 53%, and adjusted gross margin was 61%, versus 55%. The adjusted measure excludes stock-based compensation and amortization of acquisition-related intangibles.

Operating expenses rose 8% to $39.6 million. Loss from operations was $8.4 million, compared with $9.2 million, while net loss was $6.1 million versus $5.5 million. Adjusted EBITDA was $0.7 million, compared with $2.5 million. Cash, cash equivalents, restricted cash and marketable securities totaled $256.3 million as of September 30, 2026, versus $262.0 million as of June 30, 2026.

Cytek maintained the midpoint of its 2026 revenue outlook and narrowed the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates. In a separate legal update, the company said a jury found in its favor on three of four asserted claims; on the fourth, it found no literal infringement but did find infringement under the doctrine of equivalents. Cytek filed post-verdict motions and intends to pursue available legal remedies, including a potential appeal.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

How the balance works

Positive

• None.

Negative

• Moderate pointAdjusted EBITDA fell to $0.7 million from $2.5 million in 2025.
• Minor pointNet loss reached $6.1 million, versus $5.5 million in Q3 2025.

Filing Explained

The release reports 130,771,456 common shares issued and outstanding at September 30, 2026, versus 128,550,136 at December 31, 2025; the higher count means unchanged holders represented a smaller percentage of the company, absent offsetting changes.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Revenue: $53.2 million GAAP gross profit: $31.2 million GAAP gross margin: 59% +5 more

8 metrics

Revenue $53.2 million Third quarter 2026; 2% increase from the third quarter of 2025.

GAAP gross profit $31.2 million Third quarter 2026; 13% increase from the third quarter of 2025.

GAAP gross margin 59% Third quarter 2026; 53% in the third quarter of 2025.

Adjusted gross margin 61% Third quarter 2026; 55% in the third quarter of 2025.

Net loss $6.1 million Third quarter 2026; $5.5 million in the third quarter of 2025.

Adjusted EBITDA $0.7 million Third quarter 2026; $2.5 million in the third quarter of 2025.

Cash, cash equivalents, restricted cash and marketable securities $256.3 million As of September 30, 2026; $262.0 million as of June 30, 2026.

Full-year 2026 revenue outlook $208 million to $211 million Assuming no change in current foreign currency exchange rates.

Key Terms

Adjusted EBITDA, Non-GAAP adjusted gross margin, doctrine of equivalents, Full Spectrum Profiling

4 terms

Adjusted EBITDA financial

"Adjusted EBITDA was $0.7 million for the third quarter"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

Non-GAAP adjusted gross margin financial

"Non-GAAP adjusted gross margin"

Non-GAAP adjusted gross margin is the percentage of sales left after direct product or service costs, but recalculated after removing certain one-time or non-cash items that management believes obscure underlying profitability. Think of it as a cleaned-up version of the basic profit-on-sales number that aims to show how efficiently a company makes its product when you wipe away unusual or accounting-driven smudges. Investors use it to judge core operating performance, but it can vary by company and may omit real costs, so compare adjustments carefully.

doctrine of equivalents regulatory

"infringement under the doctrine of equivalents"

A patent-law principle that lets a court find infringement even when an accused product or process does not literally match the words of a patent's claims, if it performs substantially the same function in substantially the same way to achieve the same result. Like a different-shaped key that opens the same lock, it can extend a patent's practical coverage beyond its exact wording, and it matters to investors because it affects the scope of legal risk, potential damages, and the value or freedom to use technologies.

Full Spectrum Profiling technical

"patented Full Spectrum Profiling™ (FSP®) technology"

Full spectrum profiling is a comprehensive analysis that measures many types of biological signals—such as genes, proteins, metabolites and other markers—across a sample to build a broad, detailed molecular picture. For investors, it matters because that wide-ranging view can uncover new drug targets, improve predictions of which therapies will work, and support products that personalize care, much like scanning an entire toolbox instead of checking a single tool.

Earnings Snapshot

Revenue: $53.2 million · Guidance included

Third quarter ended September 30, 2026

Revenue $53.2 million 2% increase compared with the third quarter of 2025

GAAP gross profit $31.2 million 13% increase compared with the third quarter of 2025

GAAP gross margin 59% 53% in the third quarter of 2025

Net loss $6.1 million $5.5 million in the third quarter of 2025

Adjusted EBITDA $0.7 million $2.5 million in the third quarter of 2025

Guidance

Full-year 2026 revenue of $208 million to $211 million, assuming no change in current foreign currency exchange rates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did CTKB report in Q3 2026?

Cytek reported $53.2 million in third-quarter 2026 revenue, a 2% increase compared with the third quarter of 2025. U.S. revenue grew 12%, and the company also reported continued growth in service revenue.

What were CTKB's third-quarter 2026 net loss and adjusted EBITDA?

Cytek reported a third-quarter 2026 net loss of $6.1 million, compared with a $5.5 million net loss in the third quarter of 2025. Adjusted EBITDA was $0.7 million, compared with $2.5 million a year earlier.

What is CTKB's 2026 revenue outlook?

Cytek's full-year 2026 revenue outlook is $208 million to $211 million. The company said it maintained the midpoint and narrowed the range, assuming no change in current foreign currency exchange rates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001831915 0001831915 2026-11-04 2026-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 4, 2026

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40632		47-2547526
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

47215 Lakeview Boulevard Fremont, California		94538
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CTKB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2026, Cytek Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The press release is being furnished as Exhibit 99.1.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description of Exhibit
99.1		Press release dated November 4, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Cytek Biosciences, Inc.
Date: November 4, 2026				By:		/s/ Wenbin Jiang
						Wenbin Jiang, Ph.D.
						President and Chief Executive Officer

Exhibit 99.1

Cytek Biosciences Reports Third Quarter 2026 Financial Results

FREMONT, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2026.

Recent Highlights

• Total revenue for the third quarter of 2026 was $53.2 million, representing a 2% increase compared to the third quarter of 2025

• Total recurring revenue, comprised of service and reagent revenues, reached $19.1 million in the third quarter. On a trailing-12-month basis, recurring revenue represented 36% of total revenue, up from 33% on a trailing-12-month basis as of the third quarter of 2025

• Delivered GAAP gross margin of 59% representing a 590 basis point improvement compared to the third quarter of 2025

• Expanded to a total installed base of 4,073 Cytek instruments, adding 140 units in the third quarter of 2026

• Maintaining the midpoint of full year 2026 total revenue guidance and narrowing the range to $208 million to $211 million

“We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business,” said Wenbin Jiang, CEO of Cytek Biosciences. “Demand for our high-end instruments remained strong, with high-end Full Spectrum Profiling instrument revenue up 11% and Aurora Evo placements nearly doubling year over year. We also expanded gross margin by nearly 600 basis points. Looking ahead, we are reiterating the midpoint of our full-year revenue guidance and expect a strong finish to the year. We are well positioned to keep gaining market share, with our new product launches continuing to strengthen our technology leadership.”

Third Quarter 2026 Financial Results

Total revenue for the third quarter of 2026 was $53.2 million, a 2% increase compared to the third quarter of 2025. The increase in revenue was driven by growth in the U.S., led by strong demand for high-end instruments and continued growth in service.

GAAP gross profit was $31.2 million for the third quarter of 2026, a 13% increase compared to the third quarter of 2025. GAAP gross profit margin was 59% in the third quarter of 2026 compared to 53% in the third quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 61% in the third quarter of 2026 compared to 55% in the third quarter of 2025. This represents the best GAAP and adjusted gross margin for a third quarter since 2023.

Operating expenses were $39.6 million for the third quarter of 2026, an 8% increase compared to the third quarter of 2025, primarily due to higher general and administrative expenses.

Research and development expenses were $9.4 million for the third quarter of 2026, a 4% increase compared to the third quarter of 2025. The increase in expenses for the three months ended September 30, 2026 was primarily driven by higher personnel costs, offset by lower engineering expenses.

Sales and marketing expenses were $11.9 million for the third quarter of 2026, a 2% increase compared to the third quarter of 2025.

General and administrative expenses were $18.4 million for the third quarter of 2026, a 14% increase compared to the third quarter of 2025, primarily due to higher litigation-related expenses, partially offset by lower compensation and severance expenses and the non-recurrence of a write-off of deferred offering costs in the prior-year period.

Loss from operations in the third quarter of 2026 was $8.4 million, compared to loss from operations of $9.2 million in the third quarter of 2025. Net loss in the third quarter of 2026 was $6.1 million, compared to a net loss of $5.5 million in the third quarter of 2025.

Adjusted EBITDA was $0.7 million for the third quarter of 2026, compared to adjusted EBITDA of $2.5 million in the third quarter of 2025, after adjusting for stock-based compensation expense, foreign currency exchange impacts and, in the prior-year period, a non-recurring write-off of deferred at-the-market (“ATM”) facility offering costs.

Cash, cash equivalents, restricted cash and marketable securities totaled $256.3 million as of September 30, 2026, compared to $262.0 million as of June 30, 2026, a decrease of $5.7 million.

2026 Outlook

Cytek Biosciences is maintaining the midpoint of its revenue outlook for the full year 2026 and narrowing the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates.

Corporate Update

On August 21, 2026, Cytek Biosciences announced that a jury in the U.S. District Court for the District of Delaware found in Cytek’s favor on three of the four asserted claims, finding both non-infringement and invalidity for each of those three claims. On the fourth claim, the jury found no literal infringement but did find infringement under the doctrine of equivalents. Cytek Biosciences has subsequently filed post-verdict motions and intends to pursue all available legal remedies, including a potential appeal.

Webcast Information

Cytek will host a conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling^™ (FSP^®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments,

the Cytek Aurora^™, Northern Lights^™, Cytek Aurora^™ CS, Cytek Aurora^™ Evo, and Cytek Borealis^™ systems; the Cytek Orion^™ reagent cocktail preparation system; the Enhanced Small Particle^™ (ESP^™) detection technology; the flow cytometers and imaging products under the Amnis^® and Guava^® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Cytek Borealis, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Statement Regarding Use of Non-GAAP Financial Information

Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three- and nine-month periods ended September 30, 2026 and 2025. Management believes that non-GAAP financial measures, including “Adjusted gross profit,” “Adjusted gross margin,” “Adjusted EBITDA” and “Adjusted EBITDA excluding investment income,” referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s business strategies, market opportunities, product plans and

expectations, and continued investment in its products, people, and infrastructure; Cytek’s expanding installed base and future recurring revenue growth in its service and reagent businesses; Cytek’s intention to pursue additional post-trial remedies, including a potential appeal; and Cytek’s future financial performance, including its outlook for fiscal year 2026 and expectations for 2026 total revenue. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, Cytek’s Quarterly Report on Form 10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are applicable only as of the date on which they are made, and Cytek does not assume any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

Media Contact:

Stephanie Olsen

Lages & Associates

(949) 453-8080

stephanie@lages.com

Investor Contact:

Mark Meehan

Cytek Biosciences

mmeehan@cytekbio.com

Cytek Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)		September 30, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents		$	66,806			$	90,853
Restricted cash			385				—
Marketable securities			189,093				170,676
Trade accounts receivable, net			59,190				62,509
Inventories			52,371				48,428
Prepaid expenses and other current assets			11,090				19,530
Total current assets			378,935				391,996
Property and equipment, net			20,614				18,009
Operating lease right-of-use assets			10,329				11,315
Goodwill			16,691				16,697
Intangible assets, net			14,028				16,821
Other noncurrent assets			5,548				6,704
Total assets		$	446,145			$	461,542
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable		$	4,886			$	6,410
Legal settlement liability, current			2,427				2,495
Accrued expenses			27,149				23,417
Other current liabilities			20,211				16,978
Deferred revenue, current			30,281				28,504
Total current liabilities			84,954				77,804
Legal settlement liability, noncurrent			5,885				6,786
Deferred revenue, noncurrent			18,744				18,339
Operating lease liability, noncurrent			12,776				14,042
Long-term debt			99				525
Other noncurrent liabilities			2,333				2,307
Total liabilities			124,791				119,803
Stockholders’ equity:
Common stock, $0.001 par value; 1,000,000,000 authorized shares as of September 30, 2026 and December 31, 2025, respectively; 130,771,456 and 128,550,136 issued and outstanding shares as of September 30, 2026 and December 31, 2025, respectively			131				129
Additional paid-in capital			457,442				441,107
Accumulated deficit			(138,858	)			(101,738	)
Accumulated other comprehensive income			2,639				2,241
Total stockholders’ equity			321,354				341,739
Total liabilities and stockholders’ equity		$	446,145			$	461,542

Cytek Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

		Three Months Ended September 30,								Nine Months Ended September 30,
(In thousands, except share and per share data)		2026				2025				2026				2025
Revenue, net:
Product		$	37,161			$	38,114			$	98,496			$	97,639
Service			16,068				14,179				47,008				41,713
Total revenue, net			53,229				52,293				145,504				139,352
Cost of sales:
Product			14,435				17,728				43,240				48,178
Service			7,588				7,014				21,464				19,599
Total cost of sales			22,023				24,742				64,704				67,777
Gross profit			31,206				27,551				80,800				71,575
Operating expenses:
Research and development			9,355				8,956				28,700				27,506
Sales and marketing			11,911				11,666				36,731				36,309
General and administrative			18,363				16,121				53,655				42,550
Total operating expenses			39,629				36,743				119,086				106,365
Loss from operations			(8,423	)			(9,192	)			(38,286	)			(34,790	)
Other income (expense):
Interest expense			(260	)			(494	)			(803	)			(1,199	)
Interest income			1,024				573				2,630				1,636
Other income (expense), net			751				1,344				535				8,543
Total other income (expense), net			1,515				1,423				2,362				8,980
Loss before income taxes			(6,908	)			(7,769	)			(35,924	)			(25,810	)
(Benefit from) provision for income taxes			(811	)			(2,291	)			1,197				(3,347	)
Net loss		$	(6,097	)		$	(5,478	)		$	(37,121	)		$	(22,463	)
Net loss, basic and diluted		$	(6,097	)		$	(5,478	)		$	(37,121	)		$	(22,463	)
Net loss per share, basic and diluted		$	(0.05	)		$	(0.04	)		$	(0.29	)		$	(0.18	)
Weighted-average shares used in calculating net loss per share, basic and diluted			130,358,484				127,547,859				129,514,036				127,604,317
Comprehensive loss:
Net loss		$	(6,097	)		$	(5,478	)		$	(37,121	)		$	(22,463	)
Foreign currency translation adjustment, net of tax			61				741				906				784
Unrealized gain (loss) on marketable securities			(161	)			118				(509	)			20
Net comprehensive loss		$	(6,197	)		$	(4,619	)		$	(36,724	)		$	(21,659	)

Cytek Biosciences, Inc.

Reconciliation of GAAP to Non-GAAP Measures

(Unaudited)

		Three Months Ended								Nine Months Ended
(In thousands)		September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
GAAP gross profit		$	31,206			$	27,551			$	80,800			$	71,575
Stock based compensation			711				906				2,176				3,102
Amortization of acquisition-related intangible assets			490				481				1,474				1,455
Non-GAAP adjusted gross profit		$	32,407			$	28,938			$	84,450			$	76,132
GAAP gross margin			59	%			53	%			56	%			51	%
Non-GAAP adjusted gross margin			61	%			55	%			58	%			55	%
GAAP net income		$	(6,097	)		$	(5,478	)		$	(37,121	)		$	(22,463	)
Depreciation and amortization			3,109				3,063				8,906				8,932
(Benefit from) provision for income taxes			(811	)			(2,291	)			1,197				(3,347	)
Interest income			(1,024	)			(573	)			(2,630	)			(1,636	)
Interest expense			260				494				803				1,199
Foreign currency exchange loss (gain)			421				886				2,301				(1,985	)
Stock based compensation			4,853				5,638				15,054				19,058
Non-recurring deferred ATM facility offering cost write-off							711								711
Write-off Investment			—				—				1,587				—
Non-GAAP adjusted EBITDA		$	711			$	2,450			$	(9,903	)		$	469
Investment income			(1,231	)			(1,960	)			(4,244	)			(6,269	)
Non-GAAP adjusted EBITDA excluding investment income		$	(520	)		$	490			$	(14,147	)		$	(5,800	)

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 125.6 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB